Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Homology Medicines

Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022

Analyst Ratings for Homology Medicines

Analyst Ratings for Homology Medicines

Homology Medicines (NASDAQ:FIXX) has observed the following analyst ratings within the last quarter:

Homology Medicines's Return On Capital Employed Overview

Homology Medicines's Return On Capital Employed Overview

Benzinga Pro data, Homology Medicines (NASDAQ:FIXX) reported Q4 sales of $802.00 thousand. Earnings fell to a loss of $33.58 million, resulting in a 9.72% decrease from last quarter.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Analyst Ratings For Homology Medicines

Analysts have provided the following ratings for Homology Medicines (NASDAQ:FIXX) within the last quarter:

Analyst Ratings For Homology Medicines

Over the past 3 months, 4 analysts have published their opinion on Homology Medicines (NASDAQ:FIXX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Homology Medicines Stock Plunges After FDA Clinical Hold On Gene Therapy Trial

The FDA has placed a clinical hold on Homology Medicines Inc's (NASDAQ:

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Archer Aviation

Fifth Third Bancorp

Spotify Technology

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play